Sherry Li
Overview
Explore the profile of Sherry Li including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
597
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Akter N, Gordon J, Li S, Poon M, Perry S, Fletcher J, et al.
PLoS One
. 2025 Jan;
20(1):e0316919.
PMID: 39823435
Purpose: In this study, we investigated the performance of deep learning (DL) models to differentiate between normal and glaucomatous visual fields (VFs) and classify glaucoma from early to the advanced...
2.
Delaveris C, Wang C, Riley N, Li S, Kulkarni R, Bertozzi C
ACS Cent Sci
. 2023 Nov;
9(11):2108-2114.
PMID: 38033791
Neurons communicate with each other through electrochemical transmission at synapses. Microglia, the resident immune cells of the central nervous system, modulate this communication through a variety of contact-dependent and -independent...
3.
Delaveris C, Wang C, Riley N, Li S, Kulkarni R, Bertozzi C
bioRxiv
. 2023 Sep;
PMID: 37662421
Neurons communicate with each other through electrochemical transmission at synapses. Microglia, the resident immune cells of the central nervous system, can prune these synapses through a variety of contact-dependent and...
4.
Murphy D, Rini B, Escudier B, Motzer R, Wang P, Li S, et al.
Future Oncol
. 2020 May;
16(17):1199-1210.
PMID: 32363929
Immunomodulatory mechanisms contributing to angiogenic inhibition in renal tumors are not well characterized. We report associations between efficacy and tumor-associated immune cells and mRNA/miRNA expression in patients from AXIS. Immunohistochemistry...
5.
Drilon A, Clark J, Weiss J, Ou S, Camidge D, Solomon B, et al.
Nat Med
. 2020 Jan;
26(1):47-51.
PMID: 31932802
MET exon 14 alterations are oncogenic drivers of non-small-cell lung cancers (NSCLCs). These alterations are associated with increased MET activity and preclinical sensitivity to MET inhibition. Crizotinib is a multikinase...
6.
Shaw A, Solomon B, Chiari R, Riely G, Besse B, Soo R, et al.
Lancet Oncol
. 2019 Nov;
20(12):1691-1701.
PMID: 31669155
Background: Lorlatinib is a potent, brain-penetrant, third-generation tyrosine kinase inhibitor (TKI) that targets ALK and ROS1 with preclinical activity against most known resistance mutations in ALK and ROS1. We investigated...
7.
Fazio N, Martini J, Croitoru A, Schenker M, Li S, Rosbrook B, et al.
Future Oncol
. 2019 May;
15(17):1997-2007.
PMID: 31084373
Evaluate associations between clinical outcomes and SNPs in patients with well-differentiated pancreatic neuroendocrine tumors receiving sunitinib. Kaplan-Meier and Cox proportional hazards models were used to analyze the association between SNPs...
8.
Shaw A, Solomon B, Besse B, Bauer T, Lin C, Soo R, et al.
J Clin Oncol
. 2019 Mar;
37(16):1370-1379.
PMID: 30892989
Purpose: Lorlatinib is a potent, brain-penetrant, third-generation anaplastic lymphoma kinase (ALK)/ROS1 tyrosine kinase inhibitor (TKI) with robust clinical activity in advanced ALK-positive non-small-cell lung cancer, including in patients who have...
9.
George D, Martini J, Staehler M, Motzer R, Magheli A, Donskov F, et al.
Clin Cancer Res
. 2018 Nov;
25(4):1165-1173.
PMID: 30401688
Purpose: In the S-TRAC trial, adjuvant sunitinib prolonged disease-free survival (DFS) versus placebo in patients with loco-regional renal cell carcinoma at high risk of recurrence after nephrectomy. An exploratory analysis...
10.
George D, Martini J, Staehler M, Motzer R, Magheli A, Escudier B, et al.
Clin Cancer Res
. 2018 Jan;
24(7):1554-1561.
PMID: 29374054
Adjuvant sunitinib therapy compared with placebo prolonged disease-free survival (DFS) in patients with locoregional high-risk renal cell carcinoma (RCC) in the S-TRAC trial (ClinicalTrials.gov number NCT00375674). A prospectively designed exploratory...